STUDIO
SynAct Pharma summarises busy second quarter
SynAct Pharma's CEO Jeppe Øvlesen and CFO Patrik Renblad visit BioStock's studio to talk about the second quarter report, the uplisting to Nasdaq Stockholm...
RECOMMENDED READING
Aptahem increasingly close to clinical studies
BioStock reached out to Malmö company Aptahem, which is developing an emergency treatment for...
BioStock Investor Meeting, September 14
On September 14, we will arrange the next BioStock Investor Meeting, where life science...